ADAG logo

ADAGENE INC-ADR

ADAGNASDAQ
πŸ† #4065 by market capEarnings Mar 30 Β· PostUS Equity
$1.75β–Ό $0.26 (βˆ’12.94%)
Market closed Β· at close
πŸ””
Track ADAG
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 12.9%
7dβ–² 2.6%
14dβ–Ό 12.1%
30dβ–Ό 26.6%
ytdβ–Ό 7.4%
1yβ–Ό 2.8%
🏦Market Cap
$66M
Small Cap
πŸ“ˆRevenue Growth (YoY)
7332.8%
High Growth
πŸ“ŠGross Margin
94.2%
High
πŸ’΅FCF Margin
-209.0%
Thin
βš–οΈP/S Ratio
7.1x
Fair
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$1.35 – $2.00
52-Week Range
$1.27 – $4.85
Volume (shares)
12,442
Avg Volume (shares)
β€”
Shares Outstanding
37.6M
Next Earnings
2027-03-30

Fundamentals Snapshot

Annual Revenue
$8M
Last Q Revenue
$2M
P/E Ratio
-3.7
P/S Ratio
7.1x
EPS (TTM)
$-0.45
Dividend Yield
0.00%
Dilution (1yr)
+3.3%
ADAG logo

ADAGENE INC-ADR

ADAG
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$8Mβ–² +7332.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%β–Ό βˆ’112.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$21Mβ–Ό βˆ’40.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$16Mβ–Ό βˆ’47.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
37.9Mβ–² +3.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$68Mβ–² +$2M YoY
StockOtter Β· stockotter.space

About ADAGENE INC-ADR

Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and non-Hodgkin's lymphoma. Additionally, Adagene is progressing ADG126, a fully-human anti-CTLA-4 mAb, and ADG116, another human ligand-blocking anti-CTLA-4 mAb, both of which are advancing through Phase 1 studies for the treatment of advanced or metastatic solid tumors. Further along, ADG104, an anti-PD-L1 mAb, is in Phase 2 clinical development, and the innovative anti-CSF-1R mAb, ADG125, is undergoing Phase 1 trials. Beyond its clinical-stage programs, the firm also maintains an active preclinical portfolio. This includes ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is being explored for hematologic and solid tumor indications; ADG138, a novel HER2xCD3 POWERbody designed to target HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody under investigation for its potential to minimize off-tumor toxicities. Adagene Inc. was founded in 2011 and its principal operations are based in Suzhou, China.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
12 analysts
Strong Buy4
Buy7
Hold1
Sell0
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

News unavailable.